Coherus Oncology (CHRS) Gross Profit Growth (1y) (2020 - 2026)

Coherus Oncology (CHRS) Gross Profit Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 41.37%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.76%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 16.94%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 68.41%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Coherus Oncology 200.42 Mn 33.38 Mn 8.50 Mn 71.78%

Historic Data

Download Data
DateValue
Mar 31, 2026 71.78%
Dec 31, 2025 74.65%
Sep 30, 2025 136.23%
Jun 30, 2025 -19.18%
Mar 31, 2025 469.16%
Dec 31, 2024 -28.37%
Sep 30, 2024 -92.06%
Jun 30, 2024 -74.94%
Mar 31, 2024 -94.42%
Dec 31, 2023 -77.67%
Sep 30, 2023 310.84%
Jun 30, 2023 -30.70%
Mar 31, 2023 -69.33%
Dec 31, 2022 -49.14%
Sep 30, 2022 -83.36%
Jun 30, 2022 -31.11%
Mar 31, 2022 -32.81%
Dec 31, 2021 -37.98%
Sep 30, 2021 -41.44%
Jun 30, 2021 -43.48%